$NGNE
Neurogene Inc.

2020 Q2 Form 10-Q Financial Statement

#000156459020039671 Filed on August 12, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q4 2019 Q2
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.930M $3.370M $2.220M
YoY Change 122.07% 23.44% -48.49%
% of Gross Profit
Research & Development $4.843M $4.890M $10.00K
YoY Change 48330.0% 90.27% -99.94%
% of Gross Profit
Depreciation & Amortization $220.0K $340.0K
YoY Change
% of Gross Profit
Operating Expenses $9.769M $8.260M $428.0K
YoY Change 2182.48% 55.85% -98.08%
Operating Profit -$9.769M -$428.0K
YoY Change 2182.48% -115.91%
Interest Expense $40.00K $250.0K $430.0K
YoY Change -90.7% -41.86% 22.86%
% of Operating Profit
Other Income/Expense, Net $23.00K $0.00 $427.0K
YoY Change -94.61% -100.0% 87.28%
Pretax Income -$9.750M -$8.100M $0.00
YoY Change 65.64% -100.0%
Income Tax
% Of Pretax Income
Net Earnings -$9.746M -$8.100M -$1.000K
YoY Change 974500.0% 65.64% -100.03%
Net Earnings / Revenue
Basic Earnings Per Share -$0.20
Diluted Earnings Per Share -$0.20 -$232.6K $0.00
COMMON SHARES
Basic Shares Outstanding 49.39M shares 38.33M 23.54M
Diluted Shares Outstanding 49.39M shares 23.54M

Balance Sheet

Concept 2020 Q2 2019 Q4 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $129.6M $143.1M $72.70M
YoY Change 78.27% 86.09% -28.8%
Cash & Equivalents $129.6M $143.1M $72.70M
Short-Term Investments
Other Short-Term Assets $1.401M $503.0K
YoY Change
Inventory
Prepaid Expenses
Receivables $1.400M $500.0K $500.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $131.0M $143.6M $73.21M
YoY Change 78.94% 86.09% -29.09%
LONG-TERM ASSETS
Property, Plant & Equipment $3.090M $2.060M $318.0K
YoY Change 871.7% 415.0% -59.28%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.133M $30.00K $0.00
YoY Change -70.0% -100.0%
Total Long-Term Assets $14.33M $3.427M $534.0K
YoY Change 2582.96% 656.51% -54.94%
TOTAL ASSETS
Total Short-Term Assets $131.0M $143.6M $73.21M
Total Long-Term Assets $14.33M $3.427M $534.0K
Total Assets $145.3M $147.0M $73.74M
YoY Change 97.07% 89.42% -29.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.000M $4.100M $1.000M
YoY Change 500.0% -10.87% -92.48%
Accrued Expenses $200.0K $600.0K $200.0K
YoY Change 0.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $100.0K $100.0K
YoY Change
Total Short-Term Liabilities $6.300M $4.743M $1.159M
YoY Change 443.57% 2.51% -91.32%
LONG-TERM LIABILITIES
Long-Term Debt $100.0K $100.0K $0.00
YoY Change
Other Long-Term Liabilities $10.20M $400.0K $2.000K
YoY Change 509900.0% 25.39% -99.5%
Total Long-Term Liabilities $10.30M $500.0K $2.000K
YoY Change 514900.0% 56.74% -99.5%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.300M $4.743M $1.159M
Total Long-Term Liabilities $10.30M $500.0K $2.000K
Total Liabilities $16.60M $5.336M $1.414M
YoY Change 1073.97% 7.89% -89.72%
SHAREHOLDERS EQUITY
Retained Earnings -$317.9M -$299.5M -$232.3M
YoY Change 36.86% 30.18% 10.51%
Common Stock $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $128.7M $141.7M $72.33M
YoY Change
Total Liabilities & Shareholders Equity $145.3M $147.0M $73.74M
YoY Change 97.07% 89.42% -29.38%

Cashflow Statement

Concept 2020 Q2 2019 Q4 2019 Q2
OPERATING ACTIVITIES
Net Income -$9.746M -$8.100M -$1.000K
YoY Change 974500.0% 65.64% -100.03%
Depreciation, Depletion And Amortization $220.0K $340.0K
YoY Change
Cash From Operating Activities -$8.790M -$4.630M -$1.470M
YoY Change 497.96% -52.66% -116.01%
INVESTING ACTIVITIES
Capital Expenditures -$970.0K -$780.0K $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$970.0K -$780.0K $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $80.70M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 300.0K 82.21M 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -8.790M -4.630M -1.470M
Cash From Investing Activities -970.0K -780.0K 0.000
Cash From Financing Activities 300.0K 82.21M 0.000
Net Change In Cash -9.460M 76.80M -1.470M
YoY Change 543.54% -885.28% -104.52%
FREE CASH FLOW
Cash From Operating Activities -$8.790M -$4.630M -$1.470M
Capital Expenditures -$970.0K -$780.0K $0.00
Free Cash Flow -$7.820M -$3.850M -$1.470M
YoY Change 431.97% -60.63% -115.96%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Local Phone Number
LocalPhoneNumber
732-2133
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
98102
dei City Area Code
CityAreaCode
(206)
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.000001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.000001
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
145324000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
147023000
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000001
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38486542
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37996849
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38486542
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37996849
dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
503000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
770000
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
446616000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
441216000
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-317917000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-299529000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
128699000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
141687000
CY2020Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q2 nltx Research And Development Excluding Acquired In Process Research And Development
ResearchAndDevelopmentExcludingAcquiredInProcessResearchAndDevelopment
4843000
dei Trading Symbol
TradingSymbol
NLTX
dei Entity Central Index Key
EntityCentralIndexKey
0001404644
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Shell Company
EntityShellCompany
false
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Security12b Title
Security12bTitle
Common Stock, par value $0.000001
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
41749013
dei Entity File Number
EntityFileNumber
001-36327
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-0542593
dei Entity Address Address Line1
EntityAddressAddressLine1
360-1616 Eastlake Avenue East
dei Entity Address City Or Town
EntityAddressCityOrTown
Seattle
dei Entity Address State Or Province
EntityAddressStateOrProvince
WA
dei Document Transition Report
DocumentTransitionReport
false
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
129596000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
143093000
CY2020Q2 us-gaap Assets Current
AssetsCurrent
130997000
dei Document Type
DocumentType
10-Q
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Registrant Name
EntityRegistrantName
Neoleukin Therapeutics, Inc.
CY2019Q4 us-gaap Assets Current
AssetsCurrent
143596000
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3090000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2060000
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9646000
CY2020Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1133000
CY2020Q2 us-gaap Other Assets Current
OtherAssetsCurrent
1401000
CY2020Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
458000
CY2019Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
567000
CY2020Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6014000
CY2020Q2 us-gaap Assets
Assets
145324000
CY2019Q4 us-gaap Assets
Assets
147023000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
30000
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4125000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8499000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4978000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
9769000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
428000
CY2019Q2 nltx Research And Development Excluding Acquired In Process Research And Development
ResearchAndDevelopmentExcludingAcquiredInProcessResearchAndDevelopment
-1995000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
390000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
82000
us-gaap Operating Expenses
OperatingExpenses
18840000
us-gaap Operating Expenses
OperatingExpenses
3087000
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
23000
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
427000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
452000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
878000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-9746000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-1000
us-gaap Net Income Loss
NetIncomeLoss
-18388000
us-gaap Net Income Loss
NetIncomeLoss
-2209000
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.20
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
49392533
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23537368
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
49280492
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23537368
us-gaap Profit Loss
ProfitLoss
-18388000
us-gaap Profit Loss
ProfitLoss
-2209000
us-gaap Share Based Compensation
ShareBasedCompensation
1705000
us-gaap Share Based Compensation
ShareBasedCompensation
1866000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-173000
nltx Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
531000
nltx Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
52000
nltx Write Off Of Right Of Use Asset Upon Lease Termination
WriteOffOfRightOfUseAssetUponLeaseTermination
113000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
21000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-21000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
870000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
246000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1230000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3792000
nltx Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
169000
nltx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
72000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15234000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4226000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1079000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1079000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3695000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
4000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
4000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3691000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-4000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-12619000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4228000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
143093000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
76928000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
130474000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
72700000
CY2020Q2 us-gaap Deferred Offering Costs
DeferredOfferingCosts
255000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
405000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
9614000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
515000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3392000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
683000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-8642000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
137120000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
303000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1022000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
72672000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1078000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-2208000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
71542000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
788000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
72329000
us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of operations </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Neoleukin Therapeutics, Inc. (&#8220;Neoleukin&#8221; or &#8220;the Company&#8221;) is<font style="color:#000000;"> a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using</font><font style="font-style:italic;color:#000000;"> de novo </font><font style="color:#000000;">protein design technology. Neoleukin uses sophisticated computational methods to design</font><font style="font-style:italic;color:#000000;">&#160;</font><font style="Background-color:#FFFFFF;">proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins.&#160;</font></p>
nltx Tenant Improvement Allowance Receivable
TenantImprovementAllowanceReceivable
200000
CY2020Q2 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
33300
nltx Tenant Improvement Allowance
TenantImprovementAllowance
8000000
CY2020Q2 nltx Additional Tenant Improvements
AdditionalTenantImprovements
1500000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(b) Use of estimates and assumptions</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant areas requiring estimates include valuation and recognition of stock-based compensation, leases, amortization and depreciation of property, plant and equipment and intangible assets, and pre-clinical and other accruals. Actual results could differ from those estimates.</p>
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1705000
CY2020Q2 us-gaap Deposits Money Market Deposits
DepositsMoneyMarketDeposits
110100
CY2019Q4 us-gaap Deposits Money Market Deposits
DepositsMoneyMarketDeposits
40000
CY2020Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
10925481
CY2020Q2 us-gaap Security Deposit
SecurityDeposit
900000
CY2020Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
878000
nltx Termination Fees For Lease Termination
TerminationFeesForLeaseTermination
500000
nltx Operating Lease Right Of Use Asset Written Off
OperatingLeaseRightOfUseAssetWrittenOff
300000
CY2020Q2 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
200000
CY2020Q2 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
300000
CY2019Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
300000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1022000
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
788000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1866000
CY2020Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
12600
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y21D
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9361
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9209
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M25D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M28D
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0041
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0056
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5840538
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
711700
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
475193
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
463708
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5613337
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
983334
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.11
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
10.58
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.79
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
15.83
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.69
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.66
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M19D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y9M3D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
45037000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
66953000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
8861000
CY2020Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
759936
us-gaap Employee Stock Ownership Plan Esop Plan Description
EmployeeStockOwnershipPlanESOPPlanDescription
eligible employees to contribute, through payroll deductions, up to 15% of their earnings for the purchase of the Company’s shares of common stock at the lower of 85% of the closing price of the Company’s common stock on the first trading day of the offering period or 85% of the closing price of the Company’s common stock on the last trading day of the offering period
nltx Employee Stock Purchase Plan Number Of Offering Per Year
EmployeeStockPurchasePlanNumberOfOfferingPerYear
2
nltx Employee Stock Purchase Plan Offering Commencement Date
EmployeeStockPurchasePlanOfferingCommencementDate
2020-05-16
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5762348
CY2019Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2631097
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5762348
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2631097

Files In Submission

Name View Source Status
0001564590-20-039671-index-headers.html Edgar Link pending
0001564590-20-039671-index.html Edgar Link pending
0001564590-20-039671.txt Edgar Link pending
0001564590-20-039671-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g4cmattrj4wm000001.jpg Edgar Link pending
nltx-10q_20200630.htm Edgar Link pending
nltx-20200630.xml Edgar Link completed
nltx-20200630.xsd Edgar Link pending
nltx-20200630_cal.xml Edgar Link unprocessable
nltx-20200630_def.xml Edgar Link unprocessable
nltx-20200630_lab.xml Edgar Link unprocessable
nltx-20200630_pre.xml Edgar Link unprocessable
nltx-ex101_130.htm Edgar Link pending
nltx-ex102_301.htm Edgar Link pending
nltx-ex311_8.htm Edgar Link pending
nltx-ex312_6.htm Edgar Link pending
nltx-ex321_7.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending